Table 3.
Associations between skincare product use and incidence of ER+ and ER- breast cancer
| ER + breast cancera | ER- breast cancerb | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| User group of skincare products | n | Cancer cases | Age-adjusted HR (95% CI) | Multivariable HR (95% CI) | n | Cancer cases | Age-adjusted HR (95% CI) | Multivariable HR (95% CI) | pheterogeneityc |
| Non−/light users | 33,309 | 883 | 1.00 | 1.00 | 35,090 | 157 | 1.00 | 1.00 | |
| Moderate users | 22,411 | 585 | 0.98 (0.88,1.08) | 0.98 (0.89,1.09) | 23,475 | 92 | 0.89 (0.69,1.15) | 0.91 (0.7,1.18) | 0.58 |
| Frequent/heavy users | 35,784 | 948 | 0.99 (0.90,1.09) | 0.99 (0.90,1.08) | 37,896 | 159 | 0.95 (0.76,1.19) | 0.99 (0.79,1.23) | 0.99 |
HR hazard ratio, CI confidence interval; ER: estrogen receptor
aMultivariable adjusted for body mass index, smoking, age at first birth and parity combined, alcohol intake, physical activity, menopausal status, maternal breast cancer history and use of menopause hormone therapy
bMultivariable adjusted for physical activity and maternal breast cancer history
cTest of difference in effect by breast cancer subtypes